Abstract
Lysosomal sequestration may affect the pharmacokinetics, efficacy and safety of new basic lipophilic drug candidates potentially impacting their intracellular concentrations and tissue distribution. It may also be involved in drug-drug interactions, drug resistance or phospholipidosis. Currently, however, there are no assays to evaluate the lysosomotropic behaviour of compounds in a setting fully meeting the needs of drug discovery. We have therefore integrated a set of methods to reliably rank order, quantify and calculate the extent of lysosomal sequestration in rat hepatocytes. An indirect fluorescence-based assay monitors the displacement of the fluorescence probe LysoTracker™ Red by test compounds. Using a lysosomal specific evaluation algorithm allows to generate IC50 values at lower than previously reported concentrations. The concentration range directly agrees with the concentration dependency of the lysosomal drug content itself directly quantified by LC-MS/MS and thus permits a quantitative link between the indirect and the direct trapping assay. Furthermore, we have determined the full pH profile and corresponding volume fractions of the endo-/lysosomal system in plated rat hepatocytes, enabling a more accurate in silico prediction of the extent of lysosomal trapping based only on pKa values as input allowing early predictions even prior to chemical synthesis. The concentration dependency, i.e. the saturability of the trapping can then be determined by the IC50 values generated in vitro. Thereby, a more quantitative assessment of the susceptibility of basic lipophilic compounds for lysosomal trapping is possible.
- cellular trafficking/localization
- distribution
- drug toxicity
- drug-drug interactions
- hepatocytes
- liver/hepatic
- mass spectrometry/MS
- modeling and simulation
- pharmacokinetics
- physiologically-based pharmacokinetic modeling/PBPK
- The American Society for Pharmacology and Experimental Therapeutics